Additionally, daclizumab, an anti-IL-2Rα-chain (CD25) blocking antibody that has shown success in treating multiple sclerosis (MS), exerts its effect via circulatory NK cells and indirectly regulates autologous CD4+ and CD8+ T-cell numbers via granzyme activity50,51. The gene discussed is IL2RA; the disease is myeloid sarcoma.